Represents the additional contribution amount to a collaboration.

No definition available.

Name:	abbv_AdditionalContributionToCollaboration
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the additional contribution amount to a collaboration by partner.

+ References

No definition available.

+ Details

Name:	abbv_AdditionalContributionToCollaborationByPartner
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_PotentialPaymentsUnderAgreementCertainMilestones
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research and Development Milestone Expenses

+ References

No definition available.

+ Details

Name:	abbv_ResearchAndDevelopmentMilestoneExpenses
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount owed for the achievement of certain milestone(s) under an agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_ResearchandDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationWrittenoffMilestonePayment
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The upfront amount owed under an agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_ResearchandDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationWrittenoffUpfrontPayment
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) on sale or disposal of other assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainLossOnSaleOfOtherAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherOperatingIncomeExpenseNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow to acquire investments classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash inflow from the sale of other assets as part of operating activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfOtherAssets1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_SyndesiTherapeuticsSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_JuvisePharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_TeneoOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_REGENXBIOIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_IMabBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_GenmabASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_CalicoLifeSciencesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=abbv_AcquiredIPRDAndMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended					12 Months Ended
	Sep. 30, 2020	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2022	Jun. 30, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Cash outflows related to other acquisitions and investments							$ 539	$ 1,377	$ 1,350
Acquired IPR&D and milestones							697	1,124	1,376
Gain (Loss) on Disposition of Other Assets							172	68	0
Other operating expense, net							56	432	0
Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Research and Development Milestone Expenses							252	162	178
Syndesi Therapeutics SA
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones			$ 130
Syndesi Therapeutics SA \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments										$ 870
Juvise Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Proceeds from Sale of Other Assets		$ 215
TeneoOne \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones					$ 400
TeneoOne \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments					250
REGENXBIO Inc. \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones				$ 370
REGENXBIO Inc. \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments					1,400
I-Mab Biopharma \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones						$ 200
I-Mab Biopharma \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments	$ 1,700
Genmab A/S \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones									750
Genmab A/S \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments											$ 3,200
Other individually insignificant arrangements \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones							315	$ 192	$ 248
Other individually insignificant arrangements \| Maximum \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments							$ 7,500
Calico Life Sciences LLC \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Additional contribution to collaboration					500
Additional contribution to collaboration by partner					500
Other operating expense, net					$ (500)
Other operating income \| Juvise Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Gain (Loss) on Disposition of Other Assets		$ 172
Acquired IPR&D and milestones \| I-Mab Biopharma \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Upfront payment	180
Milestone payment	$ 20